• Filing Date: 2014-04-14
  • Form Type: 10-K
  • Description: Annual report
v2.4.0.8
13. SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

On January 8, 2014, the Company made payment of $375,000 to Applied Nutritionals, LLC for the 2013 royalties due.

 

On January 20, 2014, the Company received $50,000 from BioStructures, LLC upon FDA 510(k) clearance of the Bioactive Bone Graft Putty developed under an agreement between BioStrucutres, LLC and REsorbable Orthopedic Products, LLC.

 

During January 2014, the Company granted 350 shares of Series D preferred stock for services.

 

During January 2014, the Company issued 500,000 common shares which vest over 3 years and a 2% profit interest in the Case Management CellerateRX project for services rendered.

 

During January, 2014, the Company issued an aggregate of 1,087,762 shares of common stock for the conversion of notes payable with an aggregate principal amount of $90,000 and accrued interest payable in the amount of $3,729.

 

Between January and March 2014, the Company issued an aggregate of 31,087 shares of Series C preferred stock in exchange for aggregate cash proceeds of $2,176,010

 

During February and March, 2014, the Company issued an aggregate of 300,000 shares of common stock under the terms of a service agreement.

 

On March 10, 2014, the Company received $100,000 from BioStructures, LLC for the commercial license related to the Bioactive Bone Graft Putt developed under an agreement between BioStrucutres, LLC and REsorbable Orthopedic Products, LLC.

 

During March 2014, the Company granted an aggregate of 700,000 common shares to the Directors of the Company which vest immediately and awarded 500,000 common shares to the Chief Financial Officer of the Company which vest over three years.

 

During March 2014, the Company issued 30,000 common shares to a consultant for services.